Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of levocetirizine and montelukast in the treatment of autoimmune disorders

An autoimmune disease, levocetirizine technology, which is applied in the field of treating the symptoms of autoimmune diseases in patients in need, and can solve problems such as bad side effects

Inactive Publication Date: 2016-01-06
INFLAMMATORY RESPONSE RES
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Four therapeutic approaches are commonly used, but the complex etiology of the two classes of autoimmune diseases presents considerable challenges to the development of new therapies
Furthermore, many current treatment modalities, such as immunomodulatory drugs, immunosuppressive drugs, steroids, and intravenous gamma globulin, to name a few, produce side effects worse than the original disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of levocetirizine and montelukast in the treatment of autoimmune disorders
  • Use of levocetirizine and montelukast in the treatment of autoimmune disorders
  • Use of levocetirizine and montelukast in the treatment of autoimmune disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0160] Case Study: Idiopathic Thrombocytopenic Purpura (ITP).

[0161] Patient:

YS

DOB:

01 / 39 / 1969

age:

44

[0162] HPI:

[0163] A 44-year-old woman was initially seen and treated in our office in 2011 due to recurrent epistaxis secondary to longstanding ITP (idiopathic thrombocytopenic purpura). Epistaxis was treated microscopically and with silver nitrate cautery.

[0164] Past medical history had a significant impact on ITP diagnosed in 2000 and treated with prednisone and periodic IV gamma globulin. Her clinical course was complex, with streptococcal pneumonia requiring hospitalization for sepsis between 30 June 2004 and 3 July 2004. The event was aggravated by the occurrence of severe aortic regurgitation. Afterwards, YS underwent a splenectomy on September 7, 2005 in an attempt to stabilize her low platelet count due to ITP and prepare for heart surgery. She subsequently underwent a mechanical aortic valve on October 18, 2...

Embodiment ２

[0207] Case study: 69-year-old female with autoimmune neutropenia and steroid-induced diabetes.

[0208] patient

PB

DOB

02 / 13 / 1944

age

69

[0209] The patient was a 69-year-old female who was examined at the clinic in 2011 and evaluated for the presence of sphenoid sinusitis on the 2008 image. Sinusitis was accentuated by a history of chronic autoimmune neutropenia diagnosed by bone marrow biopsy in December 1997. Insecticide exposure several months before the onset of neutropenia.

[0210] Past medical history is complex, requiring Prevention of deep vein thrombosis, severe rheumatoid arthritis, hypertension and steroid-induced diabetes. Without prednisone, she experienced severe joint pain and swollen hands.

[0211] career history : Retired Computer Scientist

[0212] Major Medical Questions:

[0213] autoimmune neutropenia

[0214] severe rheumatoid arthritis

[0215] History of deep vein thrombosis and pulmonary embo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and / or modified-release elements, providing for drug delivery to the patient.

Description

[0001] Cross References to Related Applications [0002] This patent application claims the benefit of priority to US Provisional Patent Application No. 61 / 780,420, filed March 13, 2013. The foregoing applications are hereby incorporated by reference in their entirety for all purposes. Background technique [0003] Autoimmunity is described as an immune response against antigens in the host. This definition does not depend on whether the response is innate or acquired, and if acquired, whether it is induced by foreign or self antigens. In other words, if acquired, the response is induced by a foreign antigen or by an antigen found in a part of the body or in the location of the antigen's source, such as those produced by cancer. In a three-dimensional complex immune array, autoimmunity typically involves both T-cell and B-cell responses. The main requirement is an immune response against self-antigens. [0004] When dealing with human disease, it is often difficult to esta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P37/00
CPCA61K31/136A61K31/454A61K31/47A61K31/519A61K31/573A61K31/496A61K31/4985A61K31/135A61K38/193A61K31/495A61P37/00A61P37/02A61P37/06A61P43/00A61K2300/00
Inventor 布鲁斯·钱德勒·梅
Owner INFLAMMATORY RESPONSE RES